Erasca, Inc. Share Price
ERASErasca, Inc. Stock Performance
Open $11.92 | Prev. Close $12.36 | Circuit Range N/A |
Day Range $11.90 - $12.46 | Year Range $1.01 - $12.46 | Volume 3,11,480 |
Average Traded $12.28 |
Erasca, Inc. Share Price Chart
About Erasca, Inc.
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors. In addition, the company's products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Erasca, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
06-Feb-26 | $11.92 | $12.29 | +3.45% |
05-Feb-26 | $11.16 | $11.88 | +5.69% |
04-Feb-26 | $10.61 | $11.24 | +6.14% |
03-Feb-26 | $10.93 | $10.59 | -0.24% |
02-Feb-26 | $10.51 | $10.62 | +0.81% |
30-Jan-26 | $10.27 | $10.53 | +2.13% |
29-Jan-26 | $10.29 | $10.31 | +1.88% |